{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:32:24Z","timestamp":1787923944372,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    <jats:bold>Background and Objective:<\/jats:bold>\n                    Gastric and gastroesophageal junction (G\/GEJ) cancers, with their poor prognosis, pose management challenges. Treatments like perioperative chemotherapy, neoadjuvant chemoradiotherapy, and adjuvant chemotherapy aim to improve outcomes. The 5-fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) regimen has shown promise in enhancing survival. The effectiveness of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) and intra-operative radiotherapy (IORT) is still being studied. We investigated the roles of different prognostic factors and therapeutic interventions in patients with localized G\/GEJ.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A retrospective study of 65 patients diagnosed with localized G\/GEJ cancer and treated at a tertiary cancer center from January 2018 to December 2022.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Over a median follow-up of 23 months (range: 15.2\u201337.0 months), we observed a median progression-free survival (PFS) of 20 months (95% confidence interval [CI]: 8.5\u201331.5) and a median overall survival (OS) of 35.0 months (95% CI: 19.5\u201350.5). Univariate analysis revealed no statistically significant differences in OS across treatment subgroups. Notably, patients without prophylactic HIPEC\/IORT and those treated with perioperative 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) showed numerically longer PFS and OS than their counterparts.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our study supports the effectiveness of perioperative chemotherapy in localized gastric cancer, aligning with international data. However, it does not confirm FLOT\u2019s superiority over FOLFOX or the benefit of adjuvant HIPEC\/IORT in these patients.\n                  <\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-25-00040","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:00:34Z","timestamp":1773820834000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Characteristic and Clinical Outcomes of Localized Gastric Cancer: A Real-World Experience"],"prefix":"10.4103","author":[{"given":"Amal","family":"Aljuhani","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Aseafan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology, Security Forces Hospital, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Sheikh","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alhanash","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Aseer Central Hospital, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alshamsan","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Qassim University, Buraidah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tusneem","family":"Elhassan","sequence":"additional","affiliation":[{"name":"Research Unit, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouki","family":"Bazarbashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"},{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"R1-20260828","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260828"},{"key":"R3-20260828"},{"key":"R4-20260828","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-20260828","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"R6-20260828","first-page":"1","article-title":"The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas","volume":"2013","author":"Mirza","year":"2013","journal-title":"Int J Surg Oncol"},{"key":"R7-20260828","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ejso.2015.07.010","article-title":"Perioperative platinum-based chemotherapy for locally advanced esophagogastric adenocarcinoma: postoperative chemotherapy has a substantial impact on outcome","volume":"41","author":"Glatz","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"R8-20260828","first-page":"1","article-title":"Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis","volume":"5","author":"Yang","year":"2015","journal-title":"Sci Rep"},{"key":"R9-20260828","first-page":"1","article-title":"Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"key":"R10-20260828","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0000000000001143","article-title":"Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment","volume":"33","author":"G\u00fcrler","year":"2022","journal-title":"Anticancer Drugs"},{"key":"R11-20260828","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4103\/1735-5362.359430","article-title":"Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east","volume":"17","author":"Farrokhi","year":"2022","journal-title":"Res Pharm Sci"},{"key":"R12-20260828","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.29403","article-title":"NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-very good response predominantly in patients with intestinal type tumors","volume":"137","author":"Schulz","year":"2015","journal-title":"Int J Cancer"},{"key":"R13-20260828","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3892\/mco.2015.592","article-title":"Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer","volume":"3","author":"Hacibekiroglu","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"R14-20260828","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1245\/s10434-007-9487-4","article-title":"A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer","volume":"14","author":"Yan","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R15-20260828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08872-8","article-title":"Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II\/III adenocarcinoma \u2212 the phase III \u201cPREVENT\u201d- (FLOT9) trial of the AIO \/CAOGI \/ACO","volume":"21","author":"G\u00f6tze","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:02:02Z","timestamp":1787922122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":15,"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-25-00040","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}